SG11201808458QA - Compositions and methods for stabilizing alphaviruses with improved formulations - Google Patents
Compositions and methods for stabilizing alphaviruses with improved formulationsInfo
- Publication number
- SG11201808458QA SG11201808458QA SG11201808458QA SG11201808458QA SG11201808458QA SG 11201808458Q A SG11201808458Q A SG 11201808458QA SG 11201808458Q A SG11201808458Q A SG 11201808458QA SG 11201808458Q A SG11201808458Q A SG 11201808458QA SG 11201808458Q A SG11201808458Q A SG 11201808458QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- alphaviruses
- methods
- compositions
- stabilizing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 11
- 238000000034 method Methods 0.000 title abstract 5
- 241000710929 Alphavirus Species 0.000 title abstract 4
- 230000000087 stabilizing effect Effects 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 230000015556 catabolic process Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000006731 degradation reaction Methods 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
00E+02 1.00E+01 1.00E+00 1 W O 20 1717 / 26 43 Al m 1.00E+03 a 3 4 5 Formulation FIG. 1 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/172643 Al 5 October 2017 (05.10.2017) WIPO I PCT 11111111111111011101111111111101011111011101011101111111111111011111111111110111111 Loss upon lyophilization 0 Liquid 0 Week 0 (51) International Patent Classification: 9618 3 9 / 1 2 (2006.01) A61K 47/26 (2006.01) A61K 47/22 (2006.01) 961% 39/00 (2006.01) (21) International Application Number: PCT/US2017/024365 (22) International Filing Date: 27 March 2017 (27.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/316,262 31 March 2016 (31.03.2016) US (71) Applicant: TAKEDA VACCINES, INC. [US/US]; One Takeda Parkway, Deerfield, Illinois 60015 (US). (72) Inventors: LIVENGOOD, Jill Ann; 2348 Hampshire Court, Fort Collins, Colorado 80526 (US). POWELL, Timothy, Duane; 3105 Sail Place, Fort Collins, Colorado 80525 (US). (74) Agents: HANSON, Roberta et al.; 2200 Wells Fargo Cen- ter, 90 South Seventh St., Minneapolis, Minnesota 55402- 3901 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, [Continued on next page] (54) Title: COMPOSITIONS AND METHODS FOR STABILIZING ALPHAVIRUSES WITH IMPROVED FORMULATIONS (57) : Embodiments herein relate to com- positions and methods for stabilizing live alphavir- uses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated 1 00E+06 alphaviruses. Certain embodiments relate to provid- ing a stabilizing composition while reducing im- mune reaction in a subject to excipients that stabil- 1.00E+05 , ize the live alphaviruses by providing improved for- mulations. Yet other embodiments relate to uses of compositions disclosed herein in kits for portable 1.00E+04 - applications and methods wherein the compositions reduce degradation of the live alphaviruses. WO 2017/172643 Al 1#11101MOMOIDEIROIDEOMOIDE1011100111100MOVOIMIE SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Published: GW, KM, ML, MR, NE, SN, TD, TG). — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316262P | 2016-03-31 | 2016-03-31 | |
| PCT/US2017/024365 WO2017172643A1 (en) | 2016-03-31 | 2017-03-27 | Compositions and methods for stabilizing alphaviruses with improved formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808458QA true SG11201808458QA (en) | 2018-10-30 |
Family
ID=58537071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808458QA SG11201808458QA (en) | 2016-03-31 | 2017-03-27 | Compositions and methods for stabilizing alphaviruses with improved formulations |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10632184B2 (en) |
| EP (1) | EP3436063A1 (en) |
| JP (1) | JP2019513138A (en) |
| KR (1) | KR20180135912A (en) |
| CN (1) | CN109069614A (en) |
| AU (1) | AU2017241590A1 (en) |
| BR (1) | BR112018069035A2 (en) |
| CA (1) | CA3019529A1 (en) |
| CO (1) | CO2018010357A2 (en) |
| CR (1) | CR20180456A (en) |
| DO (1) | DOP2018000211A (en) |
| EC (1) | ECSP18081486A (en) |
| MX (1) | MX2018011837A (en) |
| NI (1) | NI201800096A (en) |
| PE (1) | PE20190149A1 (en) |
| PH (1) | PH12018502119A1 (en) |
| SG (1) | SG11201808458QA (en) |
| SV (1) | SV2018005747A (en) |
| WO (1) | WO2017172643A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10538785B2 (en) | 2013-12-23 | 2020-01-21 | Renaud Vaillant | Lyophilized lentiviral vector particles, compositions and methods |
| WO2021028407A1 (en) * | 2019-08-09 | 2021-02-18 | Valneva Se | Single shot chikungunya virus vaccine |
| CA3149919A1 (en) * | 2019-08-09 | 2021-02-18 | Valneva Se | Chikungunya vaccine formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545555A (en) * | 1994-07-25 | 1996-08-13 | Microtest, Inc. | Microbial transport media |
| EP2073839B1 (en) | 2006-09-01 | 2016-10-19 | Bharat Biotech International Limited | A vaccine for chikungunya virus infection |
| US9314519B2 (en) * | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| TWI690322B (en) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | Virus-containing formulation and use thereof |
| TW201900192A (en) * | 2013-03-14 | 2019-01-01 | 美商武田疫苗股份有限公司 | Composition and method for live attenuated alpha virus formula |
| CN104984357B (en) * | 2015-06-02 | 2018-01-30 | 长春百克生物科技股份公司 | Vaccine protectant composition and Gripovax without gelatin |
-
2017
- 2017-03-27 SG SG11201808458QA patent/SG11201808458QA/en unknown
- 2017-03-27 JP JP2018550558A patent/JP2019513138A/en not_active Withdrawn
- 2017-03-27 CN CN201780026126.8A patent/CN109069614A/en active Pending
- 2017-03-27 CA CA3019529A patent/CA3019529A1/en not_active Abandoned
- 2017-03-27 PE PE2018001924A patent/PE20190149A1/en unknown
- 2017-03-27 EP EP17717027.1A patent/EP3436063A1/en not_active Withdrawn
- 2017-03-27 MX MX2018011837A patent/MX2018011837A/en unknown
- 2017-03-27 CR CR20180456A patent/CR20180456A/en unknown
- 2017-03-27 AU AU2017241590A patent/AU2017241590A1/en not_active Abandoned
- 2017-03-27 KR KR1020187031479A patent/KR20180135912A/en not_active Application Discontinuation
- 2017-03-27 BR BR112018069035A patent/BR112018069035A2/en not_active IP Right Cessation
- 2017-03-27 WO PCT/US2017/024365 patent/WO2017172643A1/en active Application Filing
- 2017-03-27 US US16/088,816 patent/US10632184B2/en not_active Expired - Fee Related
-
2018
- 2018-09-27 NI NI201800096A patent/NI201800096A/en unknown
- 2018-09-27 CO CONC2018/0010357A patent/CO2018010357A2/en unknown
- 2018-09-28 SV SV2018005747A patent/SV2018005747A/en unknown
- 2018-09-28 DO DO2018000211A patent/DOP2018000211A/en unknown
- 2018-10-01 PH PH12018502119A patent/PH12018502119A1/en unknown
- 2018-10-30 EC ECSENADI201881486A patent/ECSP18081486A/en unknown
-
2020
- 2020-04-08 US US16/843,439 patent/US20200306361A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180135912A (en) | 2018-12-21 |
| MX2018011837A (en) | 2019-02-13 |
| PH12018502119A1 (en) | 2019-07-15 |
| NI201800096A (en) | 2019-02-01 |
| WO2017172643A1 (en) | 2017-10-05 |
| EP3436063A1 (en) | 2019-02-06 |
| CN109069614A (en) | 2018-12-21 |
| CO2018010357A2 (en) | 2019-05-21 |
| US10632184B2 (en) | 2020-04-28 |
| SV2018005747A (en) | 2019-03-28 |
| US20200306361A1 (en) | 2020-10-01 |
| AU2017241590A1 (en) | 2018-10-11 |
| US20190111124A1 (en) | 2019-04-18 |
| JP2019513138A (en) | 2019-05-23 |
| ECSP18081486A (en) | 2019-01-31 |
| CA3019529A1 (en) | 2017-10-05 |
| PE20190149A1 (en) | 2019-01-22 |
| CR20180456A (en) | 2019-01-09 |
| BR112018069035A2 (en) | 2019-01-29 |
| DOP2018000211A (en) | 2018-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201906795SA (en) | Novel plant cells, plants, and seeds | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201804309PA (en) | Antibody molecules to april and uses thereof | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201804770QA (en) | Method and arrangement for recovery of salt | |
| SG11202000263QA (en) | Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof | |
| SG11201909495PA (en) | Combination cancer immunotherapy with pentaaza macrocyclic ring complex | |
| SG11201809474TA (en) | Compositions and methods for bioengineered tissues | |
| SG11201804220SA (en) | Activated stem cells and systemic treatment methods for infected wounds | |
| SG11201804587QA (en) | Isoindole compounds |